Used in immunotherapy research for modulating immune responses, particularly in autoimmune diseases and cancer. Targets LILRB4 (ILT3/CD85k), a receptor on dendritic cells and monocytes that suppresses T-cell activation. By blocking this receptor, the antibody can enhance immune activation, making it valuable for developing treatments that boost anti-tumor immunity or break immune tolerance. Also employed as a reference standard in assays evaluating ILT3-binding agents and in the development of biosimilars or novel checkpoint inhibitors. Supports studies in immune checkpoint regulation and antigen-presenting cell function.